Vivanza Biosciences Limited , a company listed on the BSE, has announced several key developments in its recent board meeting held on November 11, 2025. The company has reported its quarterly results, made changes in key personnel, and proposed a significant alteration to its business objectives.

Financial Performance

The board of Vivanza Biosciences approved the unaudited financial results for the quarter ended September 30, 2025. The company reported:

These figures demonstrate the company's operational performance for the quarter, providing investors with insights into its financial health.

Changes in Key Personnel

New Company Secretary Appointment

The board, on recommendations from the Nomination and Remuneration Committee, has approved the appointment of CS Chaitra Arora as the new Company Secretary and Compliance Officer. CS Arora, holding membership number A78376, will take on this key managerial role effective November 11, 2025.

CS Arora brings experience in company law, SEBI regulations, and IPO due diligence to her new position. Her skills in drafting and practical knowledge of corporate governance, compliance, and regulatory filings are expected to be valuable assets to the company.

Previous Company Secretary's Resignation

This appointment follows the resignation of CS Siddhi Shah (Membership number A44885) from the position of Company Secretary & Compliance Officer. CS Shah's resignation, effective from September 26, 2025, was attributed to personal reasons and career advancement opportunities.

Proposed Business Expansion

The board has approved an alteration to the company's main object clause in its Memorandum of Association (MOA). This proposed change aims to expand Vivanza Biosciences' business scope to include:

• Manufacturing, processing, producing, and dealing in plastic polymer films
• Production of plastic bags and sacks from various polymers
• Manufacturing paper bags for packaging
• Developing flexible packaging materials for diverse applications

This expansion, if approved by shareholders, would mark a strategic diversification for the company, potentially opening up new revenue streams in the packaging industry.

Shareholder Approval Process

The company has initiated a postal ballot process to seek shareholder approval for the proposed alteration in the MOA. Key dates for this process include:

• Cut-off date for shareholder eligibility: November 7, 2025
• E-voting period: November 17, 2025 (9:00 AM) to December 16, 2025 (5:00 PM)
• Results declaration: By December 18, 2025

Mr. Chintan K. Patel, a Practicing Company Secretary, has been appointed as the scrutinizer for the e-voting process.

These developments indicate that Vivanza Biosciences is taking steps to strengthen its corporate governance and explore new business opportunities. Shareholders and potential investors should closely monitor these changes and their potential impact on the company's future performance and market position.

Vivanza Biosciences Limited , a pharmaceutical company, has reported a significant change in its promoter shareholding. Parth H. Parikh, a promoter of the company, has reduced his stake through an on-market transaction. The details of this transaction and its impact on the company's shareholding structure are as follows:

Transaction Details

Impact on Shareholding

Company Share Capital Information

This transaction represents a notable reduction in the promoter's stake in Vivanza Biosciences Limited. The sale of over 12 lakh shares has decreased Parth H. Parikh's shareholding by 3.08 percentage points, from 31.58% to 28.50% of the company's total share capital.

It's important to note that this disclosure was made in compliance with the Securities and Exchange Board of India (SEBI) regulations concerning substantial acquisition of shares and takeovers. Such disclosures are crucial for maintaining transparency in the stock market and keeping investors informed about significant changes in company ownership.

The reasons behind the promoter's decision to reduce their stake are not disclosed in the available information. Investors and market analysts may closely monitor further developments or any subsequent disclosures from the company for additional context regarding this shareholding change.